Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17542371 | 0.92 | KDM4E (0.41) | LMNASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL17542370 | 0.92 | KDM4E (0.41) | LMNASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL26314559 | 0.91 | ALDH1A1 (0.40) | LMNASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL26314564 | 0.90 | KMT2A (0.42) | LMNASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL17558482 | 0.89 | KDM4E (0.38) | LMNASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL29436357 | 0.89 | KDM4E (0.38) | LMNASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL17558480 | 0.89 | KDM4E (0.38) | LMNASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL18468872 | 0.88 | KDM4E (0.37) | LMNASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL22894686 | 0.87 | S1PR4 (0.51) | LMNASMN1; SMN2KDM4EALDH1A1KMT2A | |
| SCHEMBL17542388 | 0.87 | PLA2G4B (0.39) | LMNASMN1; SMN2POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | LMNA 1204/4885SMN1; SMN2 2311/4885POLB 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.